Optimizing Treatment, Biomarkers, and Chemotherapy for Patients with nmCRPC
Neal Shore, MD, FACS, outlines his treatment approach, which favors single agents over combination therapies, and incorporates bone-health drugs, vitamins, nutrition guidance, and exercise recommendations to support patients. While PSA remains a valuable biomarker in prostate cancer, he notes that ctDNA and aspects of MRD are gaining importance, although not yet widely adopted.
EP: 1.Overview of a 75-Year-old Patient with Non-Metastatic Castration-Resistant Prostate Cancer’s Case
EP: 2.Addressing Risks and Challenges in the Standard of Care for Patients with nmCRPC
EP: 3.Optimizing Treatment, Biomarkers, and Chemotherapy for Patients with nmCRPC
EP: 4.Integrating ARAMIS Trial Data and Managing Adverse Events in nmCRPC Treatment
EP: 5.Addressing Unmet Needs and Final Perspectives on nmCRPC
First Real-World Data on Second-Generation AR Inhibitor Use in nmCRPC
September 18th 2023A review of real-world data from the DEAR study of darolutamide, enzalutamide and apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer is given by Alicia Morgans, MD, MPH.
Listen
BXCL701 Gains Fast Track Designation for mCRPC Treatment
February 13th 2024The FDA has granted fast track designation to BXCL701 with an immune checkpoint inhibitor for metastatic small cell neuroendocrine prostate cancer resistant to chemotherapy and showing no evidence of microsatellite instability.
Read More
